<!DOCTYPE html>
<html lang="en">
<head>
    <meta charset="UTF-8" />
    <meta name="viewport" content="width=device-width, initial-scale=1.0"/>
    <title>COMSOL Microneedle Diffusion Analysis - Ethan Schein</title>

    <!-- Site styles & fonts -->
    <link rel="stylesheet" href="../css/style.css" />
    <link href="https://fonts.googleapis.com/css2?family=Inter:wght@300;400;500;600;700&display=swap" rel="stylesheet"/>
    <link rel="stylesheet" href="https://cdnjs.cloudflare.com/ajax/libs/font-awesome/6.4.0/css/all.min.css"/>
</head>
<body>

<!-- Loading Screen -->
<div id="loading-screen">
    <div class="loading-container">
        <div id="bike-track" class="bike-track"></div>
        <p class="loading-text">Loading<span class="loading-dots"></span></p>
    </div>
</div>

<!-- Navigation -->
<nav class="navbar">
    <div class="nav-container">
        <div class="nav-logo"><a href="../index.html">Ethan Schein</a></div>
        <ul class="nav-menu">
            <li><a href="../index.html" class="nav-link">Home</a></li>
            <li><a href="../about.html" class="nav-link">About</a></li>
            <li><a href="../education.html" class="nav-link">Education</a></li>
            <li><a href="../experience.html" class="nav-link">Experience</a></li>
            <li><a href="../projects.html" class="nav-link active">Projects</a></li>
            <li><a href="../skills.html" class="nav-link">Skills</a></li>
        </ul>
        <div class="hamburger"><span></span><span></span><span></span></div>
    </div>
</nav>

<!-- Project Detail -->
<section class="project-detail">
    <div class="container">
        <div class="back-button">
            <a href="../projects.html"><i class="fas fa-arrow-left"></i> Back to Projects</a>
        </div>

        <div class="project-header">
            <h1 class="project-title">COMSOL Analysis of Microneedle Drug Delivery Efficiency</h1>
            <div class="project-tags">
                <span class="tag">COMSOL Multiphysics</span>
                <span class="tag">Drug Delivery</span>
                <span class="tag">Finite Element Analysis</span>
                <span class="tag">Transdermal Systems</span>
                <span class="tag">Diffusion Modeling</span>
            </div>

            <!-- quick metrics -->
            <div class="key-metrics">
                <div class="metric">
                    <h4>Model Compounds</h4>
                    <p>Hydrocortisone (362.46 g/mol) & Caffeine (194.19 g/mol) as DOX surrogates</p>
                </div>
                <div class="metric">
                    <h4>Geometries Compared</h4>
                    <p>Solid (diffusion-only, Pe=0) vs Hollow (convection+diffusion, Pe=35-69)</p>
                </div>
                <div class="metric">
                    <h4>Key Finding</h4>
                    <p>Solid microneedles 2× faster to toxic threshold; partitioning dominates over diffusivity</p>
                </div>
                <div class="metric">
                    <h4>DOX Prediction</h4>
                    <p>Larger MW (543 g/mol) → slower transport; 2× solid advantage likely maintained</p>
                </div>
            </div>

            <!-- Table of contents -->
            <div class="project-toc-wrapper">
                <div class="project-toc">
                    <a href="#overview" class="toc-card">
                        <div class="toc-num">01</div>
                        <div class="toc-body">
                            <div class="toc-title">Overview</div>
                            <div class="toc-sub">Motivation & approach</div>
                        </div>
                    </a>
                    <a href="#modeling" class="toc-card">
                        <div class="toc-num">02</div>
                        <div class="toc-body">
                            <div class="toc-title">Modeling Setup</div>
                            <div class="toc-sub">Geometries & physics</div>
                        </div>
                    </a>
                    <a href="#parameters" class="toc-card">
                        <div class="toc-num">03</div>
                        <div class="toc-body">
                            <div class="toc-title">Parameters</div>
                            <div class="toc-sub">Material properties & transport</div>
                        </div>
                    </a>
                    <a href="#results" class="toc-card">
                        <div class="toc-num">04</div>
                        <div class="toc-body">
                            <div class="toc-title">Results</div>
                            <div class="toc-sub">Hydrocortisone & caffeine</div>
                        </div>
                    </a>
                    <a href="#analysis" class="toc-card">
                        <div class="toc-num">05</div>
                        <div class="toc-body">
                            <div class="toc-title">Analysis</div>
                            <div class="toc-sub">Transport mechanisms</div>
                        </div>
                    </a>
                    <a href="#conclusions" class="toc-card">
                        <div class="toc-num">06</div>
                        <div class="toc-body">
                            <div class="toc-title">Conclusions</div>
                            <div class="toc-sub">Findings & DOX predictions</div>
                        </div>
                    </a>
                </div>
            </div>
        </div>

        <div class="project-content">

            <!-- Overview -->
            <div id="overview" class="project-section">
                <h2>Overview</h2>
                <p>
                    Transdermal drug delivery offers significant advantages over oral and injectable routes: it bypasses first-pass hepatic metabolism, maintains steady-state plasma concentrations, and improves patient compliance by eliminating injection pain. However, the skin's stratum corneum acts as a formidable barrier to most therapeutic molecules, limiting passive diffusion to compounds <500 Da with optimal lipophilicity. Microneedles—micron-scale projections that penetrate the stratum corneum without reaching pain receptors—have emerged as a minimally invasive strategy to enhance transdermal bioavailability.
                </p>
                <p>
                    This project evaluates two competing microneedle architectures using <strong>COMSOL Multiphysics</strong> finite element modeling: <em>solid microneedles</em> with surface drug coatings relying on passive diffusion, and <em>hollow microneedles</em> with internal lumens enabling active convective delivery. To predict the behavior of <strong>doxorubicin (DOX)</strong>—a 543 g/mol chemotherapy agent with poor skin permeability—I characterized the transport dynamics of two model compounds: <strong>hydrocortisone</strong> (362.46 g/mol, corticosteroid) and <strong>caffeine</strong> (194.19 g/mol, xanthine alkaloid). These surrogates span a range of molecular weights and partition coefficients, enabling mechanistic insights into size-dependent and lipophilicity-dependent transport.
                </p>
                <div class="callout">
                    <strong>Research Question:</strong> Which microneedle geometry—solid (diffusion-only) or hollow (convection+diffusion)—delivers drugs more efficiently to the dermis and bloodstream? How do molecular properties (MW, partition coefficient, diffusivity) influence delivery kinetics, and what does this predict for doxorubicin transport?
                </div>
            </div>

            <!-- Modeling Setup -->
            <div id="modeling" class="project-section">
                <h2>COMSOL Modeling Setup & Geometry</h2>

                <details open>
                    <summary>Solid Microneedle Configuration — Passive Diffusion Architecture</summary>

                    <h4>Design Rationale</h4>
                    <p>
                        Solid microneedles rely entirely on <strong>passive diffusion</strong> from a drug coating applied to the needle surface. This architecture is mechanically robust (no hollow bore to collapse), simple to manufacture (no alignment of internal channels), and well-suited for poorly soluble drugs that can be formulated into coatings. However, delivery is limited by the drug's intrinsic diffusion coefficient and partition coefficient across skin layers.
                    </p>

                    <h4>Geometric Specifications</h4>
                    <ul class="project-list">
                        <li><strong>Needle length:</strong> 500 μm (sufficient to penetrate stratum corneum and reach viable epidermis; avoids dermal pain receptors)</li>
                        <li><strong>Needle geometry:</strong> Tapered conical profile (100 μm base diameter tapering to sharp tip); mimics commercial microneedle arrays</li>
                        <li><strong>Drug coating:</strong> Uniform 10 μm layer on external surface; initial concentration C₀ = 1000 μg/mL</li>
                        <li><strong>Insertion depth:</strong> Full 500 μm penetration into skin; coating contacts both epidermis and upper dermis</li>
                    </ul>

                    <h4>Physics Implementation</h4>
                    <p>
                        Transport governed by <strong>Fick's Second Law</strong> (pure diffusion):
                    </p>
                    <p style="text-align: center; font-family: 'Courier New', monospace; background: #f5f5f5; padding: 1rem; border-radius: 4px;">
                        ∂C/∂t = D∇²C
                    </p>
                    <ul class="project-list">
                        <li><strong>No convection:</strong> Péclet number Pe = 0 (velocity = 0)</li>
                        <li><strong>Boundary conditions:</strong> Fixed concentration at coating interface (C = C₀); zero flux at needle core; continuity at epidermis-dermis boundary</li>
                        <li><strong>Mesh:</strong> Finer mesh near coating-skin interface (element size ~1 μm) to resolve steep concentration gradients; coarser in bulk tissue (element size ~20 μm)</li>
                    </ul>

                    <figure class="figure">
                        <img class="project-img max-400 img-center"
                             src="../assets/images/comsol-microneedle/solid-microneedle-fixed.jpg"
                             alt="Solid microneedle geometry with tapered profile and surface coating"
                             width="1400" height="1000" loading="lazy" decoding="async" />
                        <figcaption class="caption">Solid microneedle geometry: 500 μm tapered needle with 10 μm drug coating (red); drug diffuses passively into epidermis (yellow) and dermis (pink).</figcaption>
                    </figure>
                </details>

                <details open>
                    <summary>Hollow Microneedle Configuration — Convection-Diffusion Architecture</summary>

                    <h4>Design Rationale</h4>
                    <p>
                        Hollow microneedles enable <strong>active delivery</strong> by pumping drug solution through an internal lumen directly into tissue. This architecture provides precise control over delivery rate (via flow rate adjustment), enables delivery of large molecules that diffuse poorly, and can achieve higher local concentrations than coating-based systems. However, it requires more complex fabrication (boring internal channels), alignment of the lumen with a reservoir, and potential for clogging or flow obstruction.
                    </p>

                    <h4>Geometric Specifications</h4>
                    <ul class="project-list">
                        <li><strong>Needle length:</strong> 500 μm (identical to solid for fair comparison)</li>
                        <li><strong>Outer diameter:</strong> 100 μm (matches solid needle base)</li>
                        <li><strong>Lumen diameter:</strong> 40 μm (internal bore running full needle length)</li>
                        <li><strong>Wall thickness:</strong> 30 μm (sufficient structural integrity to prevent collapse during insertion)</li>
                        <li><strong>Reservoir connection:</strong> Lumen inlet at base connects to drug reservoir maintained at C₀ = 1000 μg/mL</li>
                    </ul>

                    <h4>Physics Implementation</h4>
                    <p>
                        Transport governed by <strong>convection-diffusion equation</strong>:
                    </p>
                    <p style="text-align: center; font-family: 'Courier New', monospace; background: #f5f5f5; padding: 1rem; border-radius: 4px;">
                        ∂C/∂t + v·∇C = D∇²C
                    </p>
                    <ul class="project-list">
                        <li><strong>Flow velocity:</strong> v = 2.976 × 10⁻⁴ m/s (uniform plug flow in lumen; representative of syringe pump delivery)</li>
                        <li><strong>Péclet number:</strong> Pe = vL/D = (2.976×10⁻⁴ m/s × 500×10⁻⁶ m) / D</li>
                        <li><strong>Hydrocortisone:</strong> Pe = 68.9 (convection dominates 69× over diffusion)</li>
                        <li><strong>Caffeine:</strong> Pe = 35.2 (convection dominates 35× over diffusion)</li>
                        <li><strong>Boundary conditions:</strong> Inlet: C = C₀ (reservoir concentration); outlet: convective flux at lumen-tissue interface; no-slip velocity at lumen walls</li>
                    </ul>

                    <figure class="figure">
                        <img class="project-img max-400 img-center"
                             src="../assets/images/comsol-microneedle/hollow-microneedle-fixed.jpg"
                             alt="Hollow microneedle with internal lumen and convective flow"
                             width="1400" height="1000" loading="lazy" decoding="async" />
                        <figcaption class="caption">Hollow microneedle geometry: 40 μm internal lumen (blue arrows show flow direction); drug delivered via convection directly into dermis; outlet at lumen tip.</figcaption>
                    </figure>
                </details>

                <details>
                    <summary>Skin Layer Geometry & Physiological Parameters</summary>

                    <h4>Epidermis Layer</h4>
                    <ul class="project-list">
                        <li><strong>Thickness:</strong> 100 μm (representative of viable epidermis beneath stratum corneum)</li>
                        <li><strong>Structure:</strong> Stratified squamous epithelium; keratinocytes in various differentiation stages</li>
                        <li><strong>Density:</strong> ρ = 1200 kg/m³ (slightly higher than water due to keratinization)</li>
                        <li><strong>Tortuosity:</strong> Intercellular lipid bilayers create tortuous diffusion pathways; effective diffusion coefficient reduced vs. aqueous solution</li>
                    </ul>

                    <h4>Dermis Layer</h4>
                    <ul class="project-list">
                        <li><strong>Thickness:</strong> 1000 μm (includes papillary and upper reticular dermis; sufficient depth to model diffusion into capillary network)</li>
                        <li><strong>Structure:</strong> Collagen/elastin matrix with microcirculation; ~70% water content</li>
                        <li><strong>Density:</strong> ρ = 1000 kg/m³ (approximates aqueous tissue)</li>
                        <li><strong>Capillary sink:</strong> Perfect sink boundary condition at dermis bottom (C = 0) represents rapid clearance by blood flow; mimics systemic absorption</li>
                    </ul>

                    <h4>Interface Conditions</h4>
                    <p>
                        At the epidermis-dermis boundary, I imposed <strong>continuity of concentration and flux</strong>:
                    </p>
                    <ul class="project-list">
                        <li>C_epidermis = C_dermis (no concentration jump)</li>
                        <li>-D_epidermis ∇C_epidermis = -D_dermis ∇C_dermis (flux conservation)</li>
                        <li>Partition coefficient differences across layers handled implicitly via layer-specific diffusivity</li>
                    </ul>
                </details>
            </div>

            <!-- Parameters -->
            <div id="parameters" class="project-section">
                <h2>Material Properties & Transport Parameters</h2>

                <details open>
                    <summary>Hydrocortisone — Physicochemical Properties & Selection Rationale</summary>

                    <h4>Why Hydrocortisone as a Model Compound?</h4>
                    <p>
                        Hydrocortisone (MW = 362.46 g/mol) is a <strong>synthetic corticosteroid</strong> with extensive transdermal literature, making it an ideal benchmark for validating COMSOL models against experimental data. Its molecular weight falls between caffeine and doxorubicin, and its lipophilicity (log P ≈ 1.6) represents moderate skin partitioning. Clinically, hydrocortisone is delivered transdermally for anti-inflammatory therapy, so the modeling directly informs real-world applications.
                    </p>

                    <h4>Diffusion Coefficients</h4>
                    <ul class="project-list">
                        <li><strong>Aqueous solution:</strong> D₀ = 2.16 × 10⁻⁹ cm²/s (calculated via Stokes-Einstein for 25°C)</li>
                        <li><strong>Epidermis:</strong> D_epi = 1.08 × 10⁻¹⁰ cm²/s (20-fold reduction due to lipid barrier tortuosity)</li>
                        <li><strong>Dermis:</strong> D_derm = 1.73 × 10⁻⁹ cm²/s (only ~20% reduction vs. aqueous; dermis is ~70% water)</li>
                        <li><strong>Temperature dependence:</strong> All values at physiological 37°C; Arrhenius correction applied for skin surface (32°C)</li>
                    </ul>

                    <h4>Partition Coefficients</h4>
                    <p>
                        Partition coefficients (K) quantify drug partitioning between adjacent phases. Higher K indicates preferential accumulation in the target phase.
                    </p>
                    <ul class="project-list">
                        <li><strong>Stratum corneum/epidermis:</strong> K_sc/epi = 0.15 (hydrocortisone prefers lipid-rich stratum corneum over aqueous epidermis)</li>
                        <li><strong>Epidermis/dermis:</strong> K_epi/derm = 0.92 (near unity; similar lipid content)</li>
                        <li><strong>Dermis/blood:</strong> K_derm/blood = 1.05 (favorable for systemic clearance)</li>
                    </ul>

                    <h4>Solubility & Concentration Limits</h4>
                    <ul class="project-list">
                        <li><strong>Aqueous solubility:</strong> 320 μg/mL at 25°C (limits reservoir concentration)</li>
                        <li><strong>Coating concentration:</strong> C₀ = 1000 μg/mL (supersaturated via polymer matrix; maintains high driving force)</li>
                        <li><strong>Toxic threshold:</strong> 10 μg/mL in dermis (represents systemic exposure limit; used to calculate delivery efficiency)</li>
                    </ul>

                    <figure class="figure">
                        <img class="project-img max-500 img-center"
                             src="../assets/images/comsol-microneedle/tableofvals%20(2).jpg"
                             alt="Table of hydrocortisone transport parameters"
                             width="1400" height="1000" loading="lazy" decoding="async" />
                        <figcaption class="caption">Hydrocortisone transport parameters: diffusion coefficients, partition coefficients, and layer-specific properties used in COMSOL simulations.</figcaption>
                    </figure>
                </details>

                <details open>
                    <summary>Caffeine — Physicochemical Properties & Selection Rationale</summary>

                    <h4>Why Caffeine as a Complementary Model?</h4>
                    <p>
                        Caffeine (MW = 194.19 g/mol) is a <strong>methylxanthine alkaloid</strong> with fundamentally different properties from hydrocortisone: smaller molecular size (2× smaller), higher polarity (log P ≈ −0.07), and faster aqueous diffusion. By comparing hydrocortisone (lipophilic, moderate MW) to caffeine (hydrophilic, small MW), I can decouple the effects of <em>molecular size</em> vs. <em>partition coefficient</em> on delivery efficiency—critical for predicting doxorubicin behavior.
                    </p>

                    <h4>Diffusion Coefficients</h4>
                    <ul class="project-list">
                        <li><strong>Aqueous solution:</strong> D₀ = 4.23 × 10⁻⁹ cm²/s (2× faster than hydrocortisone due to smaller hydrodynamic radius)</li>
                        <li><strong>Epidermis:</strong> D_epi = 2.54 × 10⁻¹⁰ cm²/s (17-fold reduction; lipid barrier still rate-limiting despite higher diffusivity)</li>
                        <li><strong>Dermis:</strong> D_derm = 3.81 × 10⁻⁹ cm²/s (2× faster than hydrocortisone; aqueous dermis favors small polar molecules)</li>
                    </ul>

                    <h4>Partition Coefficients</h4>
                    <ul class="project-list">
                        <li><strong>Stratum corneum/epidermis:</strong> K_sc/epi = 0.05 (low partitioning into lipid-rich SC; caffeine prefers aqueous environments)</li>
                        <li><strong>Epidermis/dermis:</strong> K_epi/derm = 1.12 (slightly favors dermis; follows hydrophilicity)</li>
                        <li><strong>Dermis/blood:</strong> K_derm/blood = 0.98 (near unity; rapid clearance)</li>
                    </ul>

                    <h4>Key Difference from Hydrocortisone</h4>
                    <div class="callout">
                        <strong>Trade-off:</strong> Caffeine's <em>higher diffusivity</em> (4.23 vs. 2.16 × 10⁻⁹ cm²/s) is offset by its <em>lower partition coefficient</em> into the epidermis (0.05 vs. 0.15). This creates a scenario where <strong>partitioning becomes more important than diffusivity</strong> for determining initial skin uptake—a finding with direct implications for doxorubicin (large, hydrophilic molecule with expected low partition coefficients).
                    </div>
                </details>

                <details>
                    <summary>Péclet Number Analysis — Identifying Dominant Transport Mechanisms</summary>

                    <h4>Theoretical Background</h4>
                    <p>
                        The <strong>Péclet number (Pe)</strong> is a dimensionless quantity comparing convective transport to diffusive transport:
                    </p>
                    <p style="text-align: center; font-family: 'Courier New', monospace; background: #f5f5f5; padding: 1rem; border-radius: 4px;">
                        Pe = vL/D
                    </p>
                    <p>
                        where v is characteristic velocity, L is characteristic length, and D is diffusion coefficient. Interpretation:
                    </p>
                    <ul class="project-list">
                        <li><strong>Pe ≪ 1:</strong> Diffusion dominates; concentration gradients smooth out rapidly; transport time scales as L²/D</li>
                        <li><strong>Pe ≈ 1:</strong> Convection and diffusion equally important; requires full convection-diffusion equation</li>
                        <li><strong>Pe ≫ 1:</strong> Convection dominates; sharp concentration fronts; transport time scales as L/v</li>
                    </ul>

                    <h4>Calculated Values for Each System</h4>

                    <h5>Solid Microneedle (Both Drugs)</h5>
                    <ul class="project-list">
                        <li>Velocity v = 0 (no flow)</li>
                        <li><strong>Pe = 0</strong></li>
                        <li><strong>Mechanism:</strong> Pure diffusion; justified use of Fick's Second Law without convective term</li>
                    </ul>

                    <h5>Hollow Microneedle — Hydrocortisone</h5>
                    <ul class="project-list">
                        <li>v = 2.976 × 10⁻⁴ m/s (syringe pump flow rate)</li>
                        <li>L = 500 μm (lumen length)</li>
                        <li>D = 2.16 × 10⁻⁹ cm²/s = 2.16 × 10⁻¹³ m²/s</li>
                        <li><strong>Pe = (2.976×10⁻⁴ × 500×10⁻⁶) / (2.16×10⁻¹³) = 68.9</strong></li>
                        <li><strong>Mechanism:</strong> Convection dominates 69× over diffusion; concentration front advected downstream; diffusion only relevant near lumen walls</li>
                    </ul>

                    <h5>Hollow Microneedle — Caffeine</h5>
                    <ul class="project-list">
                        <li>Same v and L as hydrocortisone</li>
                        <li>D = 4.23 × 10⁻⁹ cm²/s = 4.23 × 10⁻¹³ m²/s (2× higher than hydrocortisone)</li>
                        <li><strong>Pe = (2.976×10⁻⁴ × 500×10⁻⁶) / (4.23×10⁻¹³) = 35.2</strong></li>
                        <li><strong>Mechanism:</strong> Convection still dominates 35× over diffusion, but relatively more diffusive spreading than hydrocortisone</li>
                    </ul>

                    <div class="callout">
                        <strong>Implication:</strong> Since Pe ≫ 1 for both drugs in hollow microneedles, <strong>convection is the primary transport mechanism</strong> within the lumen. However, once drug exits the lumen into tissue, diffusion becomes important (Pe ~ 0 in static tissue). This creates a <em>two-stage delivery process</em>: fast convective delivery to tissue interface, then slower diffusive penetration into dermis.
                    </div>

                    <figure class="figure">
                        <img class="project-img max-500 img-center"
                             src="../assets/images/comsol-microneedle/graphics.jpg"
                             alt="Schematic of Péclet number regimes showing diffusion vs convection dominance"
                             width="1400" height="1000" loading="lazy" decoding="async" />
                        <figcaption class="caption">Transport regime comparison: Pe ≪ 1 (diffusion-dominated; smooth gradients) vs. Pe ≫ 1 (convection-dominated; sharp fronts); epidermis acts as barrier in both cases.</figcaption>
                    </figure>
                </details>

                <details>
                    <summary>Controlled Variables & Validation Strategy</summary>

                    <h4>Variables Held Constant Across All Simulations</h4>
                    <p>
                        To ensure fair comparison between solid and hollow microneedles, I maintained identical geometry and boundary conditions, varying only the <em>transport mechanism</em> (diffusion-only vs. convection+diffusion) and <em>drug properties</em> (D, K for each compound):
                    </p>
                    <ul class="project-list">
                        <li><strong>Needle length:</strong> 500 μm</li>
                        <li><strong>Needle base diameter:</strong> 100 μm</li>
                        <li><strong>Epidermis thickness:</strong> 100 μm</li>
                        <li><strong>Dermis thickness:</strong> 1000 μm</li>
                        <li><strong>Initial drug concentration:</strong> C₀ = 1000 μg/mL</li>
                        <li><strong>Sink boundary:</strong> C = 0 at dermis-blood interface (perfect clearance)</li>
                        <li><strong>Temperature:</strong> 37°C (physiological)</li>
                        <li><strong>Simulation time:</strong> 3600 s (1 hour)</li>
                    </ul>

                    <h4>Validation Against Literature</h4>
                    <p>
                        I validated model predictions against published experimental data:
                    </p>
                    <ul class="project-list">
                        <li><strong>Hydrocortisone flux:</strong> Predicted 2.1 μg/cm²/h vs. literature 1.8-2.5 μg/cm²/h (within experimental variability)</li>
                        <li><strong>Caffeine permeability coefficient:</strong> Predicted Kp = 3.2 × 10⁻⁶ cm/s vs. literature 2.8-3.6 × 10⁻⁶ cm/s</li>
                        <li><strong>Qualitative trends:</strong> Smaller molecules penetrate faster (caffeine > hydrocortisone in dermis at t > 30 min); lipophilic molecules show higher epidermal retention (hydrocortisone > caffeine in epidermis)</li>
                    </ul>
                </details>
            </div>

            <!-- Results -->
            <div id="results" class="project-section">
                <h2>Results & Quantitative Analysis</h2>

                <details open>
                    <summary>Hydrocortisone Delivery — Concentration Distributions & Time Evolution</summary>

                    <h4>Spatial Distribution Comparison</h4>
                    <p>
                        Hydrocortisone concentration profiles reveal fundamentally different delivery mechanisms between solid and hollow microneedles. Solid needles produce <strong>broad radial diffusion</strong> from the coating surface, creating a hemispherical concentration gradient extending ~200 μm laterally into the dermis. In contrast, hollow needles produce <strong>localized jets</strong> at the lumen outlet, with drug confined to a ~50 μm radius around the tip—an effect of high Péclet number convection.
                    </p>

                    <figure class="figure">
                        <img class="project-img max-600 img-center"
                             src="../assets/images/comsol-microneedle/hydrocortisone.png"
                             alt="Hydrocortisone concentration comparison between solid and hollow microneedles"
                             width="1400" height="1000" loading="lazy" decoding="async" />
                        <figcaption class="caption">Hydrocortisone concentration distribution at t = 600s: Solid microneedle (left) shows broad diffusive spreading into dermis; hollow microneedle (right) shows localized jet at lumen outlet with slower lateral diffusion.</figcaption>
                    </figure>

                    <h4>Time to Toxic Threshold (10 μg/mL in Dermis)</h4>
                    <ul class="project-list">
                        <li><strong>Solid microneedle:</strong> t_toxic = 420 s (7 minutes)</li>
                        <li><strong>Hollow microneedle:</strong> t_toxic = 840 s (14 minutes)</li>
                        <li><strong>Efficiency ratio:</strong> 840 / 420 = <strong>2.0</strong> (solid is 2× faster)</li>
                    </ul>

                    <h4>Mechanistic Interpretation</h4>
                    <p>
                        The 2× efficiency advantage of solid microneedles arises from <strong>superior spatial distribution</strong> rather than absolute delivery rate. Although hollow needles deliver drug faster to the lumen outlet (high Pe convection), the drug remains confined near the injection point. Solid needles achieve lower peak concentrations but distribute drug over a much larger volume, accelerating the onset of systemic exposure. This finding challenges the conventional assumption that "active delivery = faster delivery"—for transdermal systems, <em>distribution efficiency matters more than injection rate</em>.
                    </p>
                </details>

                <details open>
                    <summary>Caffeine Delivery — Comparing Size vs. Partitioning Effects</summary>

                    <h4>Spatial Distribution Comparison</h4>
                    <p>
                        Caffeine exhibits similar geometric patterns to hydrocortisone (broad diffusion for solid, localized jet for hollow) but with <strong>faster absolute diffusion</strong> due to its 2× higher diffusivity. However, caffeine's lower partition coefficient into the epidermis (K = 0.05 vs. 0.15 for hydrocortisone) creates a <em>delayed onset</em> despite faster diffusion—a counterintuitive result demonstrating that <strong>partitioning can be rate-limiting even when diffusivity is high</strong>.
                    </p>

                    <figure class="figure">
                        <img class="project-img max-600 img-center"
                             src="../assets/images/comsol-microneedle/caffeine.png"
                             alt="Caffeine concentration profiles for solid and hollow microneedles"
                             width="1400" height="1000" loading="lazy" decoding="async" />
                        <figcaption class="caption">Caffeine concentration distribution at t = 600s: Similar solid vs. hollow geometric trends as hydrocortisone, but with faster overall diffusion due to smaller molecular size (194 vs. 362 g/mol).</figcaption>
                    </figure>

                    <h4>Time to Toxic Threshold (10 μg/mL in Dermis)</h4>
                    <ul class="project-list">
                        <li><strong>Solid microneedle:</strong> t_toxic = 380 s (6.3 minutes)</li>
                        <li><strong>Hollow microneedle:</strong> t_toxic = 760 s (12.7 minutes)</li>
                        <li><strong>Efficiency ratio:</strong> 760 / 380 = <strong>2.0</strong> (solid is 2× faster, identical to hydrocortisone)</li>
                    </ul>

                    <h4>Caffeine vs. Hydrocortisone Comparison</h4>
                    <div class="callout">
                        <strong>Key Finding:</strong> Caffeine reaches toxic threshold <em>faster</em> than hydrocortisone (380s vs. 420s for solid needles) despite having <strong>lower partition coefficient</strong> (0.05 vs. 0.15). This demonstrates that for <em>dermis delivery</em>, caffeine's 2× higher diffusivity overcomes its partitioning disadvantage. However, for <em>epidermis accumulation</em>, hydrocortisone shows higher concentrations due to favorable lipid partitioning. This trade-off has direct implications for doxorubicin: as a large, hydrophilic molecule, DOX will likely show <strong>both</strong> slow diffusion <strong>and</strong> poor partitioning, compounding delivery challenges.
                    </div>
                </details>

                <details>
                    <summary>Efficiency Ratio Analysis — Why 2.0 for Both Drugs?</summary>

                    <h4>Observation</h4>
                    <p>
                        The efficiency ratio (hollow/solid time to reach 10 μg/mL) is <strong>exactly 2.0 for both hydrocortisone and caffeine</strong>. This consistency suggests a fundamental geometric relationship independent of drug properties.
                    </p>

                    <h4>Mechanistic Explanation</h4>
                    <p>
                        The 2× factor arises from the <strong>volumetric distribution advantage</strong> of solid microneedles:
                    </p>
                    <ul class="project-list">
                        <li><strong>Solid needle:</strong> Drug diffuses from entire 500 μm coating surface → hemispherical spreading pattern → volume of distribution ∝ 4πr³/3 where r ≈ 200 μm → V_solid ≈ 33.5 mm³</li>
                        <li><strong>Hollow needle:</strong> Drug injected from single point (lumen outlet) → cylindrical jet pattern → volume of distribution ≈ πr²h where r ≈ 50 μm, h ≈ 500 μm → V_hollow ≈ 3.9 mm³</li>
                        <li><strong>Volume ratio:</strong> V_solid / V_hollow ≈ 8.6× (solid distributes drug over 8.6× larger volume)</li>
                    </ul>

                    <p>
                        However, the efficiency ratio is only 2×, not 8.6×, because:
                    </p>
                    <ul class="project-list">
                        <li>Hollow needles achieve <strong>higher peak concentrations</strong> locally (convection delivers drug faster than diffusion)</li>
                        <li>Toxic threshold is reached when <em>average dermis concentration</em> hits 10 μg/mL, not peak concentration</li>
                        <li>Solid needles' broader distribution means lower peak but faster approach to threshold <em>on average</em></li>
                    </ul>

                    <h4>Why Independent of Drug Properties?</h4>
                    <p>
                        The 2× ratio holds for both drugs because it's determined by <strong>geometric delivery architecture</strong>, not molecular diffusivity or partitioning. While caffeine diffuses 2× faster than hydrocortisone (D_caff = 4.23 vs. D_hydro = 2.16 × 10⁻⁹ cm²/s), this factor affects <em>absolute delivery times</em> (380s vs. 420s) but not the <em>solid-to-hollow ratio</em>, which is set by the volume-of-distribution mismatch.
                    </p>
                </details>
            </div>

            <!-- Analysis -->
            <div id="analysis" class="project-section">
                <h2>Discussion & Transport Mechanism Analysis</h2>

                <details open>
                    <summary>Partitioning vs. Diffusivity — Which Matters More for Skin Delivery?</summary>

                    <h4>Conventional Wisdom: Diffusivity Dominates</h4>
                    <p>
                        Classical drug delivery models (e.g., Higuchi equation) predict that transdermal flux is proportional to <strong>√(D × C_sat)</strong>, where D is diffusion coefficient and C_sat is solubility. This suggests smaller, faster-diffusing molecules should always penetrate better. However, these models assume <em>partition equilibrium</em>—they don't account for partitioning kinetics at layer interfaces.
                    </p>

                    <h4>Observed Behavior: Partitioning Can Dominate</h4>
                    <p>
                        Hydrocortisone reaches toxic threshold only marginally slower than caffeine (420s vs. 380s for solid needles) despite having <strong>50% lower diffusivity</strong> (2.16 vs. 4.23 × 10⁻⁹ cm²/s). This is because hydrocortisone's <strong>3× higher partition coefficient</strong> into the epidermis (0.15 vs. 0.05) creates a larger initial driving force for permeation. The epidermis acts as a <em>concentrating reservoir</em> for lipophilic drugs, maintaining higher steady-state flux into the dermis.
                    </p>

                    <h4>Implications for Doxorubicin</h4>
                    <div class="callout">
                        <strong>DOX Prediction:</strong> Doxorubicin (MW = 543 g/mol, log P ≈ 1.27) is both <em>larger</em> (lower diffusivity) and <em>more hydrophilic at physiological pH</em> (lower partition coefficient) than hydrocortisone. Using the Stokes-Einstein equation to estimate DOX diffusivity:
                        <p style="margin-top: 0.5rem; font-family: 'Courier New', monospace; background: #f5f5f5; padding: 0.5rem; border-radius: 4px;">
                            D_DOX ≈ D_hydro × (MW_hydro / MW_DOX)^(1/3) ≈ 2.16 × 10⁻⁹ × (362/543)^(1/3) ≈ 1.9 × 10⁻⁹ cm²/s
                        </p>
                        This predicts DOX will diffuse ~12% slower than hydrocortisone. However, DOX's <strong>ionizable amine group</strong> (pKa ≈ 8.2) means it exists partially charged at pH 7.4, severely reducing lipid partitioning. Expected K_DOX ≈ 0.02-0.05 (similar to caffeine or lower), compounding transport limitations. Net result: <strong>DOX delivery likely 3-5× slower than hydrocortisone</strong> due to combined diffusivity and partitioning deficits.
                    </div>
                </details>

                <details open>
                    <summary>Convection vs. Diffusion — Rethinking "Active Delivery" Assumptions</summary>

                    <h4>Conventional Expectation: Active Delivery Should Be Faster</h4>
                    <p>
                        Hollow microneedles enable "active delivery" via pressurized injection, leading to the assumption that they should deliver drugs faster than "passive" solid microneedles. Pharmaceutical literature often cites convection's superior transport efficiency (Pe ≫ 1 means rapid advection) as justification for hollow designs.
                    </p>

                    <h4>Observed Paradox: Passive Outperforms Active (2× Faster)</h4>
                    <p>
                        My results show solid microneedles are consistently 2× faster to toxic threshold despite relying purely on diffusion (Pe = 0). This apparent paradox resolves when considering <strong>distribution efficiency vs. injection rate</strong>:
                    </p>
                    <ul class="project-list">
                        <li><strong>Hollow needles:</strong> High Pe convection delivers drug rapidly to lumen outlet → peak concentration ~500 μg/mL within 50 μm of tip → but drug remains localized (slow lateral diffusion) → dermis as a whole takes longer to reach threshold</li>
                        <li><strong>Solid needles:</strong> Diffusion from 500 μm coating surface → lower peak (~100 μg/mL) but spread over 200 μm radius → dermis volume-averaged concentration rises faster → threshold reached sooner</li>
                    </ul>

                    <h4>Clinical Relevance</h4>
                    <p>
                        This finding has significant implications for microneedle design philosophy:
                    </p>
                    <div class="callout">
                        <strong>Design Insight:</strong> For transdermal drug delivery where the goal is <em>systemic exposure</em> (dermis → bloodstream), <strong>spatial distribution matters more than injection rate</strong>. Hollow microneedles are advantageous when targeting <em>local dermal structures</em> (e.g., immune cells for vaccination, dermal fibroblasts for cosmetic treatments) because high local concentrations are beneficial. However, for <em>systemic drug delivery</em> (e.g., chemotherapy, hormone replacement), solid microneedles' broader distribution enables faster onset despite slower individual delivery rates.
                        <br><br>
                        For doxorubicin chemotherapy patches, this suggests <strong>solid microneedle arrays with high surface density</strong> (maximizing coating area) may outperform hollow designs, contradicting the intuition that "injection is better than diffusion."
                    </div>
                </details>

                <details>
                    <summary>Péclet Number Regime Transitions — Two-Stage Delivery Process</summary>

                    <h4>Stage 1: Convection-Dominated Lumen Transport (Pe = 35-69)</h4>
                    <p>
                        Inside hollow microneedle lumens, high Péclet numbers (68.9 for hydrocortisone, 35.2 for caffeine) indicate that drug is primarily <strong>advected by bulk flow</strong>. Concentration profiles within the lumen show sharp fronts propagating at velocity v = 2.976 × 10⁻⁴ m/s with minimal radial spreading. Transport time through 500 μm lumen:
                    </p>
                    <p style="font-family: 'Courier New', monospace; background: #f5f5f5; padding: 0.5rem; border-radius: 4px;">
                        t_lumen = L/v = (500 × 10⁻⁶ m) / (2.976 × 10⁻⁴ m/s) ≈ 1.68 s
                    </p>
                    <p>
                        This extremely fast delivery to the lumen outlet is why hollow needles achieve high local concentrations quickly.
                    </p>

                    <h4>Stage 2: Diffusion-Dominated Tissue Transport (Pe ≈ 0)</h4>
                    <p>
                        Once drug exits the lumen into static dermal tissue, convection ceases (no bulk flow in extracellular matrix) and transport becomes <strong>purely diffusive</strong>. Characteristic diffusion time to spread 200 μm laterally:
                    </p>
                    <p style="font-family: 'Courier New', monospace; background: #f5f5f5; padding: 0.5rem; border-radius: 4px;">
                        t_diffusion = L² / (6D) = (200 × 10⁻⁶)² / (6 × 2.16 × 10⁻¹³) ≈ 31 s (hydrocortisone)
                    </p>
                    <p>
                        This ~20× slower lateral spreading (31s vs. 1.68s lumen transit) is the bottleneck for hollow needle delivery. Although drug reaches the dermis quickly, it takes much longer to distribute to concentrations relevant for systemic exposure.
                    </p>

                    <h4>Solid Microneedle Bypasses This Limitation</h4>
                    <p>
                        Solid microneedles avoid the two-stage bottleneck by delivering drug <strong>directly to a large surface area</strong> (entire 500 μm coating) rather than a single point. Diffusion distances are inherently shorter (~100 μm from coating surface to dermis mid-plane vs. ~200 μm lateral spreading from lumen outlet), enabling faster volume-averaged delivery despite lower peak rates.
                    </p>
                </details>

                <details>
                    <summary>Limitations & Model Assumptions</summary>

                    <h4>Physiological Simplifications</h4>
                    <ul class="project-list">
                        <li><strong>Perfect sink assumption:</strong> Model assumes instantaneous blood clearance (C = 0 at dermis boundary); reality involves finite capillary permeability and plasma protein binding → actual clearance slower, may accumulate drug in dermis</li>
                        <li><strong>Static tissue:</strong> Neglects dermal blood flow, lymphatic drainage, and interstitial fluid movement → all provide additional convective transport mechanisms not captured</li>
                        <li><strong>Homogeneous layers:</strong> Treats epidermis and dermis as uniform phases; ignores hair follicles, sebaceous glands, and sweat ducts (which provide "shunt pathways" for enhanced permeation)</li>
                        <li><strong>No metabolism:</strong> Assumes drug remains chemically stable; in reality, epidermal enzymes (CYP450s, esterases) can degrade drugs during permeation</li>
                    </ul>

                    <h4>Geometric Idealizations</h4>
                    <ul class="project-list">
                        <li><strong>Perfect insertion:</strong> Model assumes microneedle penetrates exactly 500 μm perpendicular to skin; actual insertion angles vary (±5-10°), affecting delivery depth</li>
                        <li><strong>No tissue deformation:</strong> Skin compresses and deforms around microneedles; this creates local tissue density changes not accounted for</li>
                        <li><strong>Single needle:</strong> Clinical arrays use 50-400 needles/cm²; model scales linearly (× number of needles) but ignores inter-needle diffusion overlap</li>
                    </ul>

                    <h4>Impact on Predictions</h4>
                    <p>
                        These limitations likely cause the model to <strong>underestimate absolute delivery times</strong> (real tissue has more transport barriers) but should not affect the <strong>solid vs. hollow comparison</strong> (both geometries experience the same tissue complexity). The 2× efficiency ratio is robust to these assumptions because it's determined by geometric distribution differences, not absolute transport rates.
                    </p>
                </details>
            </div>

            <!-- Conclusions -->
            <div id="conclusions" class="project-section">
                <h2>Conclusions & DOX Delivery Predictions</h2>

                <h3>Key Findings Summary</h3>
                <ol class="project-list">
                    <li><strong>Solid microneedles deliver 2× faster to systemic threshold:</strong> Both hydrocortisone and caffeine showed efficiency ratios of 2.0 (hollow/solid), indicating solid needles reach toxic dermis concentrations in half the time despite relying on passive diffusion.</li>

                    <li><strong>Distribution efficiency dominates over injection rate:</strong> Hollow microneedles' high Péclet number convection (Pe = 35-69) creates rapid local delivery but poor spatial distribution. Solid microneedles' broad surface-area delivery enables faster volume-averaged permeation to bloodstream.</li>

                    <li><strong>Partitioning can be more important than diffusivity:</strong> Hydrocortisone reached toxic threshold nearly as fast as caffeine (420s vs. 380s) despite 50% slower diffusion, due to 3× higher partition coefficient. This demonstrates that for lipid-barrier-limited transport, <strong>favorable partitioning > high diffusivity</strong>.</li>

                    <li><strong>Péclet analysis validates two-stage hollow needle transport:</strong> Convection dominates within lumen (Pe ≫ 1, transit time ~1.7s) but diffusion bottleneck in tissue (Pe ≈ 0, lateral spreading ~31s) limits overall efficiency.</li>

                    <li><strong>Efficiency ratio is geometry-dependent, not drug-dependent:</strong> The 2× factor derives from volumetric distribution mismatch (solid spreads over ~8.6× larger volume) and holds for both test compounds, suggesting it will apply to DOX as well.</li>
                </ol>

                <h3>Doxorubicin (DOX) Delivery Predictions</h3>
                <div class="callout">
                    <strong>Expected DOX Transport Characteristics:</strong>
                    <ul class="project-list" style="margin-top: 0.5rem;">
                        <li><strong>Molecular weight:</strong> 543 g/mol → ~12% slower diffusion than hydrocortisone (Stokes-Einstein scaling)</li>
                        <li><strong>Ionization state:</strong> pKa ≈ 8.2 (amine), 10.2 (phenol) → partially charged at pH 7.4 → poor lipid partitioning (K ≈ 0.02-0.05, similar to or worse than caffeine)</li>
                        <li><strong>Combined effect:</strong> Slower diffusion + poor partitioning → DOX likely <strong>3-5× slower to reach toxic threshold</strong> than hydrocortisone</li>
                        <li><strong>Solid vs. hollow:</strong> 2× efficiency advantage of solid microneedles should persist (geometry-determined), making solid needles <strong>6-10× faster than hollow for DOX delivery</strong> if combined with the 3-5× drug property penalty</li>
                    </ul>

                    <strong>Clinical Translation for DOX Patches:</strong>
                    <br>For transdermal doxorubicin chemotherapy (avoiding IV infusion toxicity), this work suggests:
                    <ul class="project-list" style="margin-top: 0.5rem;">
                        <li>Use <strong>high-density solid microneedle arrays</strong> (400+ needles/cm²) with drug-loaded coatings</li>
                        <li>Expect onset times of ~20-30 minutes to reach therapeutic plasma levels (vs. 7-14 min for hydrocortisone)</li>
                        <li>Consider <strong>penetration enhancers</strong> (e.g., surfactants, chemical permeation enhancers) to improve DOX partitioning into lipid barriers</li>
                        <li>Hollow needles may be viable only if combined with <strong>iontophoresis or electroporation</strong> to overcome diffusion limitations in tissue</li>
                    </ul>
                </div>

                <h3>Technical Skills Demonstrated</h3>
                <div class="key-metrics">
                    <div class="metric">
                        <h4>COMSOL Multiphysics Modeling</h4>
                        <p>Finite element method, convection-diffusion physics, parametric sweeps, mesh refinement, boundary condition implementation, multi-domain coupling</p>
                    </div>
                    <div class="metric">
                        <h4>Transport Phenomena Analysis</h4>
                        <p>Péclet number calculations, dimensionless analysis, regime identification, partition coefficient effects, diffusion-limited vs. partition-limited transport</p>
                    </div>
                    <div class="metric">
                        <h4>Drug Delivery Engineering</h4>
                        <p>Transdermal permeation theory, microneedle design principles, pharmacokinetic predictions, skin physiology, bioavailability optimization</p>
                    </div>
                    <div class="metric">
                        <h4>Quantitative Comparison & Validation</h4>
                        <p>Controlled variable methodology, efficiency ratio calculations, literature benchmarking, error analysis, extrapolation to untested compounds</p>
                    </div>
                </div>

                <h3>Future Directions</h3>
                <ul class="project-list">
                    <li><strong>Experimental validation:</strong> Franz diffusion cell studies with human cadaver skin to confirm 2× efficiency ratio and validate DOX predictions</li>
                    <li><strong>Multi-needle array modeling:</strong> Extend to 100-400 needle arrays with inter-needle diffusion overlap; optimize spacing for maximum delivery rate</li>
                    <li><strong>Dynamic coating dissolution:</strong> Model time-dependent coating depletion (current model assumes infinite reservoir); impacts long-term sustained release</li>
                    <li><strong>Convection enhancement strategies:</strong> Evaluate iontophoresis (electric field-driven), electroporation (transient pore formation), and ultrasound (acoustic streaming) to improve hollow needle efficiency</li>
                    <li><strong>In vivo pharmacokinetics:</strong> Compare model predictions to animal PK data; validate plasma concentration vs. time profiles</li>
                </ul>
            </div>

        </div>
    </div>
</section>

<script src="../js/script.js"></script>
<script src="../js/script.js"></script>
</body>
</html>